Full text is available at the source.
Abstract
Major adverse cardiovascular events (MACE) following carotid artery stenting (CAS) remain clinically significant.
- Pharmacological options to lower cardiovascular risk after CAS are limited beyond standard treatments.
- Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) have been shown to reduce MACE in type 2 diabetes patients with cardiovascular disease.
- There is a lack of specific data on the effectiveness of GLP-1 RA therapy in patients undergoing CAS.
Simplified